Research Studies:
HALO
(HIV, ARTERIAL DYSFUNCTION, LIPIDS, OMACOR®)
HALO is a study assessing the safety and effectiveness of Omacor® (Omega-3 fats or fish oil) on lipids in HIV positive individuals. Omega-3 Fatty Acids have been studied in cardiovascular disease and have been shown to reduce serum lipids, however, the effect of these fish oils on serum lipids among people with HIV infection is less clear.
Purpose: |
The purpose of this clinical study is to assess the efficacy of Omacor® (Omega-3 Fatty Acids) on serum lipids in HIV-infected individuals. The study will also explore effects on flow-mediated dilation of the brachial artery. |
Eligibility
Criteria: |
- HIV-positive adults at least 18 years of age
- Evidence of high triglycerides (>150 mg/dl)
- Taking antiretroviral medications for 12 weeks prior to study entry
|
Study
Requirements: |
This 24-week study is designed for HIV-positive volunteers who have evidence of abnormal serum triglycerides or HDL cholesterol and have been taking antiretroviral medications for at least 12 weeks prior to study entry.
Volunteers will be randomly assigned to one of two groups: active drug or placebo (i.e. dummy medication which does not have any activity). This study will compare the use of Omacor® to placebo. All volunteers will receive the active medication, Omacor®, by the end of the study. |
Study
Personnel: |
| Christine Wanke,
MD |
Principal Investigator |
| Alexandra Mangili, MD, MPH |
Co-Investigator |
| Jeffrey Kuvin, MD |
Co-Investigator |
| Jül Gerrior, RD |
Research Coordinator |
|
Contact: |
| Jül Gerrior, RD |
(617) 636-0492 |
CURRENTLY ENROLLING
Privacy and confidentiality are strictly
maintained.
TOP
|
|
